Termination TerugBetaalRegeling Forxiga® - Hartfalen

30 June 2021

Termination TerugBetaalRegeling Forxiga® - Hartfalen

From July 1st 2021 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of heart failure with reduced ejection fraction (HFrEF) is fully reimbursed by the health insurer. The reimbursement for heart failure is independent of the diabetes status of the patient. Therefore the ‘TerugBetaalRegeling Forxiga® (dapagliflozine) 10 mg voor hartfalen’ has been closed. The manufacturer of this medicine has reimbursed the costs of the personal contribution to the patient from November 5 2020 till June 30 2021.


The Personal Contribution for Forxiga® (dapagliflozine) 10 mg that is demonstrably charged to the patient by the health insurer was fully reimbursed from November 5 2020 till June 30 2021. Only prescriptions dispensed between these mentioned dates can be claimed through TerugBetaalRegeling Nederland until December 31 2021.

For your information: The ‘TerugBetaalRegeling' for patients type 2 diabetes without heart failure remains open at this time.

Who can submit a claim

Patients or their caregivers can claim the Personal Contribution Forxiga® (dapagliflozine) 10 mg online or by post. Online will be the fastest option. Pharmacists can also claim this medicine on behalf of the patient. This can only be submitted online.

For more information check out the Forxiga® (dapagliflozine) 10 mg for heart failure medicine page

NL-7115 EXP 31/05/22

You are currently offline. Some pages or content may fail to load.